Zhejiang University School of Medicine | China
Professor Xianguo Chen is a distinguished thoracic surgeon and senior medical expert at the School of Medicine, Zhejiang University, where he serves as Professor and Chief Physician at the Affiliated Jinhua Hospital. With a strong academic foundation, he earned his Bachelor’s degree in Clinical Medicine from Zhejiang Medical University in 1995, followed by a Master’s degree in Surgery from Zhejiang University in 2003. Over nearly three decades of clinical and research experience, Professor Chen has established himself as a leading figure in thoracic oncology, pulmonary diseases, and precision cancer therapeutics. His professional journey at Zhejiang University’s Affiliated Jinhua Hospital began in 1996, advancing from Physician to Attending Physician in 2000, Associate Chief Physician in 2006, and Chief Physician in 2011, reflecting his outstanding clinical expertise, leadership, and dedication to patient care. Professor Chen’s research interests lie at the intersection of thoracic surgery, molecular oncology, targeted cancer therapy, and tumor metabolism. He has led several high-impact scientific projects funded by provincial and municipal agencies. These include a major Jinhua Science and Technology Plan project investigating the regulatory effects of acacetin on SMYD2-mediated DNA damage repair inhibition, a provincial health science project exploring the mechanism by which KMT3C mediates osimertinib resistance in non-small cell lung cancer through ENO1-driven glycolysis, and an influential study on pulmonary nodule differentiation and lung cancer progression involving metabolomics and fecal microbiota transplantation. His research has made significant contributions to understanding tumor resistance mechanisms, novel biomarkers, and innovative therapeutic strategies for lung cancer. An accomplished scholar, Professor Chen has authored numerous publications in internationally recognized journals. His recent works include studies on miR-1293 and angiogenesis in lung adenocarcinoma, carbonic anhydrase 4 as a prognostic biomarker for NSCLC, identification of novel RET fusions and ALK translocations, and advancements in postoperative drainage techniques for lung cancer surgery. As first author, corresponding author, or co-corresponding author, his publications reflect his strong commitment to advancing thoracic oncology research. Beyond clinical and research excellence, Professor Chen plays a vital leadership role in several professional medical organizations. He serves as Vice Chairman of the Thoracic Surgery Branch of the Zhejiang Medical Association, Executive Vice Chairman of the Cardiothoracic Surgery Branch of the Jinhua Medical Association, and holds additional appointments in regional cancer prevention and thoracic surgery committees. Through his multifaceted contributions, Professor Xianguo Chen continues to shape the future of thoracic surgery and lung cancer research in China and beyond.
Featured Publications
Lou, Y., Xu, B., Huang, K., Li, X., Jin, H., Ding, L., Ning, S., & Chen, X. (2024). Knockdown of miR-1293 attenuates lung adenocarcinoma angiogenesis via Spry4 upregulation-mediated ERK1/2 signaling inhibition. Biochemical Pharmacology, 226, 116414.
Xu, B., Lou, Y., Xu, X., Li, X., Tian, X., Yu, Z., & Chen, X. (2023). Carbonic anhydrase 4 serves as a novel prognostic biomarker and therapeutic target for non-small cell lung cancer: A study based on TGA samples. Combinatorial Chemistry & High Throughput Screening, 26(14), 2527–2540.
Xu, X., Wang, H., Yu, Z., & Chen, X. (2022). A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: A case report. Journal of Cancer Research and Clinical Oncology, 148(7), 1825–1827.
Chen, X., Xu, B., Fu, F., Cai, K., & Yu, Z. (2021). A novel nonreciprocal/reciprocal ALK translocation causing ALK+ in NSCLC. Lung Cancer, 158, 162–163.
Li, X., Chen, X., He, S., & Chen, H. (2021). The application of pigtail catheters in postoperative drainage of lung cancer. Clinical Lung Cancer, 23(3), e196–e202.